跳至主要内容
临床试验/NCT00266721
NCT00266721已完成3 期

Efficacy of Pancrelipase on Postprandial Belching and Bloating.

Solvay Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2000年1月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
45
试验地点
2
主要终点
Abdominal bloating

研究概览

简要总结

The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation.

详细描述

Subjects will complete a double-blind crossover study in which, for one week periods, they will receive two pancrelipase tablets with each of the three major meals or a similarly administered identical placebo. Three times daily, subjects will rate the severity of belching, epigastric discomfort, epigastric fullness, bloating, and nausea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects will have either bothersome upper abdominal discomfort, bloating (feeling of abdominal distention) or belching following meals for at least 12 month's duration. Subjects must have had a normal upper gastrointestinal endoscopy and/or upper GI series during the preceding three years.

排除标准

  • Individuals with a history suggestive of organic disease such as recent weight loss, nausea, vomiting, GERD, recent changes in bowel habits will be excluded from the study.

结局指标

主要结局

Abdominal bloating

Abdominal pain

Eructation

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验